Early bird
tickets
available now!
Get HCM digital magazine and ezines FREE
Sign up here ▸
Jobs   News   Features   Products   Magazine      Advertise  
NEWS
Unexpected benefits of weight loss drugs revealed
POSTED 18 Jun 2024 . BY Kath Hudson
Weight-loss drugs can help with mental health Credit: Mohammed_Al_Ali
Studies show GLP-1 drugs have benefits beyond weight loss
They can be used to treat mental health, addictions, some eating disorders and neurodegeneration
As well as suppressing appetite, it appears they can also suppress addictive cravings
Neuroinflammation is dampened down and cognition and emotional processing areas of the brain stimulated
According to a number of recent studies, semaglutide weight-loss drugs can be effective in treating depression, anxiety, dementia, addiction and some eating disorders.

There is a great deal of research, and more ongoing, which shows the broad-ranging benefits of weight loss drugs, which could potentially lead to them being prescribed for a range of illnesses in the future.

The drugs work for weight loss by mimicking the hormone, glucagon-like peptide-1 (GLP-1), which is produced by the gut and brain, and leads to an increased feeling of satiety. As GLP-1 receptors are peppered throughout the brain – including areas important for cognitive functions and emotional control, such as the prefrontal cortex, hippocampus and amygdala – research shows that stimulating these receptors could be beneficial for other health issues too.

Rodrigo Mansur, from the University of Toronto, led a small study giving liraglutide to 19 people with major depressive disorder or bipolar disorder and within a month they reported better mood, attention span and cognitive function. MRI scans of the participants’ brains revealed that the areas involved in planning, organisation and emotional processing significantly increased in volume within a month. Mansur is now conducting a randomised controlled trial to investigate the ability of GLP-1 drugs to directly treat mood disorders.

GLP-1 has also been shown to increase the brain’s blood flow, slow down the death of nerve cells and promote the flow of glucose to the brain, which is an incredibly sugar-hungry organ, consuming up to 20 per cent of calories. Some studies show that GLP-1 modulates the transport of glucose across the blood-brain barrier, slows the rate at which the brain consumes glucose, reduces oxidative stress and damps down inflammation, which leads to cardiovascular benefits.

Some studies have shown benefits of treating brain diseases, such as Parkinson’s and Alzheimer’s, which are characterised by neuroinflammation. Pharmaceutical company, Novo Nordisk, is currently working on two trials testing semaglutide for Alzheimer’s disease. There is hope these drugs could also help other brain conditions, such as epilepsy and stroke.

A study at Penn State Neuroscience Institute used anti-obesity drugs to treat opioid addiction and found a 40 per cent reduction in opioid cravings over three weeks compared with those receiving a placebo. Researchers suspect the drugs target addiction in a similar way to hunger drive, by influencing the two areas of the brain involved with reward processing and cravings. A larger trial is now underway.

Last year, University of Oklahoma found that semaglutide was more effective in helping people with binge eating disorder than the only medication currently approved by the US Food and Drug Administration (FDA) for this condition. Other evidence suggests that GLP-1s might also help treat bulimia nervosa, an eating disorder which presents as bingeing and purging.

However, there are a few snags with what appears to be a wonder drug. Widespread use of weight-loss medication might lead to further idealisation of slim bodies. It is not yet known if people who aren’t overweight can take GLP-1s safely for mental health reasons alone, as reducing their appetite could lead to malnourishment or becoming critically underweight. For this reason they are not suitable for people suffering from the eating disorder, anorexia nervosa, even though it often stems from anxiety and is an addiction to restricting food.

The research studies have been published in New Scientist magazine.



RELATED STORIES
  Equinox launches specialist programmes for members on weight loss drugs


US premium operator, Equinox, is the first operator to create an educational programme for its coaches on how to train individuals who have lost weight with the help of drugs.
  FEATURE: Editor's letter: Weight loss drugs


Weight loss drugs are hitting the mainstream, with pilot programmes underway. Liz Terry examines the threats and opportunities this creates for the sector
  FEATURE: Policy: Weighing in


A £40m pilot for the delivery of weight loss drugs, such as Wegovy, is creating opportunities for the sector
MORE NEWS
All systems go for GoJoe app with Les Mills partnership, investment and campaigns
Employee wellness app GoJoe has teamed up with Les Mills for a major new content offering, giving access to hundreds of new workouts.
Gymbox partners with Raza Sana to transform lives through fitness
Gymbox has partnered with Haringey Council and not-for-profit organisation, Raza Sana, to give opportunities to those living in disadvantaged communities.
Sport for Confidence gets national recognition for pioneering work breaking down barriers to physical activity
Sport for Confidence CIC has received a national award for its pioneering work hardwiring occupational therapy driven services into community sport and leisure settings.
Mindbody adds bespoke insurance to its list of offerings
Mindbody, has launched a specialist insurance programme for its customers which is being delivered through its platform.
+ More news   
LATEST JOBS
Health and Fitness Instructor
Bolton Arena
Salary: £Competitive + pension + benefits
Job location: Bolton, Greater Manchester , United Kingdom
+ More jobs  

FEATURED SUPPLIERS

THFI’s new online coaching course partners with FITR: launch your business confidently post-completion
In today's rapidly evolving fitness industry, where many online courses promise secret formulas for entrepreneurial success, the reality is that few provide the necessary knowledge to thrive in this fast-changing profession. [more...]

Altrafit introduces custom functional fitness equipment at Third Space
Altrafit has taken further steps to cement its reputation as a provider of high-quality, affordable functional fitness equipment that is built to last with the development and introduction of a new functional fitness keg for luxury gym operator, Third Space. [more...]
+ More featured suppliers  
COMPANY PROFILES
Orbit4

Orbit4 is the ultimate software solution for operators to manage their fitness facility. [more...]
Serco Leisure

Serco Leisure Operating Limited is one of the UK’s leading national operators of leisure centres, de [more...]
+ More profiles  
CATALOGUE GALLERY
 
+ More catalogues  

DIRECTORY
+ More directory  
DIARY

 

28-29 Jul 2024

Les Nouvelles Esthetiques Spa Conference 2024

Southern Sun Rosebank, Johannesburg, South Africa
03-05 Sep 2024

ASEAN Patio Pool Spa Expo

IMPACT Exhibition Center, Bangkok, Thailand
+ More diary  
 
ABOUT LEISURE MEDIA
LEISURE MEDIA MAGAZINES
LEISURE MEDIA HANDBOOKS
LEISURE MEDIA WEBSITES
LEISURE MEDIA PRODUCT SEARCH
 
HCM
LEISURE OPPORTUNITIES
HEALTH CLUB HANDBOOK
PRINT SUBSCRIPTIONS
FREE DIGITAL SUBSCRIPTIONS
ADVERTISE . CONTACT US

Leisure Media
Tel: +44 (0)1462 431385

©Cybertrek 2024
Get HCM digital magazine and ezines FREE
Sign up here ▸
Jobs    News   Products   Magazine
NEWS
Unexpected benefits of weight loss drugs revealed
POSTED 18 Jun 2024 . BY Kath Hudson
Weight-loss drugs can help with mental health Credit: Mohammed_Al_Ali
Studies show GLP-1 drugs have benefits beyond weight loss
They can be used to treat mental health, addictions, some eating disorders and neurodegeneration
As well as suppressing appetite, it appears they can also suppress addictive cravings
Neuroinflammation is dampened down and cognition and emotional processing areas of the brain stimulated
According to a number of recent studies, semaglutide weight-loss drugs can be effective in treating depression, anxiety, dementia, addiction and some eating disorders.

There is a great deal of research, and more ongoing, which shows the broad-ranging benefits of weight loss drugs, which could potentially lead to them being prescribed for a range of illnesses in the future.

The drugs work for weight loss by mimicking the hormone, glucagon-like peptide-1 (GLP-1), which is produced by the gut and brain, and leads to an increased feeling of satiety. As GLP-1 receptors are peppered throughout the brain – including areas important for cognitive functions and emotional control, such as the prefrontal cortex, hippocampus and amygdala – research shows that stimulating these receptors could be beneficial for other health issues too.

Rodrigo Mansur, from the University of Toronto, led a small study giving liraglutide to 19 people with major depressive disorder or bipolar disorder and within a month they reported better mood, attention span and cognitive function. MRI scans of the participants’ brains revealed that the areas involved in planning, organisation and emotional processing significantly increased in volume within a month. Mansur is now conducting a randomised controlled trial to investigate the ability of GLP-1 drugs to directly treat mood disorders.

GLP-1 has also been shown to increase the brain’s blood flow, slow down the death of nerve cells and promote the flow of glucose to the brain, which is an incredibly sugar-hungry organ, consuming up to 20 per cent of calories. Some studies show that GLP-1 modulates the transport of glucose across the blood-brain barrier, slows the rate at which the brain consumes glucose, reduces oxidative stress and damps down inflammation, which leads to cardiovascular benefits.

Some studies have shown benefits of treating brain diseases, such as Parkinson’s and Alzheimer’s, which are characterised by neuroinflammation. Pharmaceutical company, Novo Nordisk, is currently working on two trials testing semaglutide for Alzheimer’s disease. There is hope these drugs could also help other brain conditions, such as epilepsy and stroke.

A study at Penn State Neuroscience Institute used anti-obesity drugs to treat opioid addiction and found a 40 per cent reduction in opioid cravings over three weeks compared with those receiving a placebo. Researchers suspect the drugs target addiction in a similar way to hunger drive, by influencing the two areas of the brain involved with reward processing and cravings. A larger trial is now underway.

Last year, University of Oklahoma found that semaglutide was more effective in helping people with binge eating disorder than the only medication currently approved by the US Food and Drug Administration (FDA) for this condition. Other evidence suggests that GLP-1s might also help treat bulimia nervosa, an eating disorder which presents as bingeing and purging.

However, there are a few snags with what appears to be a wonder drug. Widespread use of weight-loss medication might lead to further idealisation of slim bodies. It is not yet known if people who aren’t overweight can take GLP-1s safely for mental health reasons alone, as reducing their appetite could lead to malnourishment or becoming critically underweight. For this reason they are not suitable for people suffering from the eating disorder, anorexia nervosa, even though it often stems from anxiety and is an addiction to restricting food.

The research studies have been published in New Scientist magazine.



RELATED STORIES
Equinox launches specialist programmes for members on weight loss drugs


US premium operator, Equinox, is the first operator to create an educational programme for its coaches on how to train individuals who have lost weight with the help of drugs.
FEATURE: Editor's letter: Weight loss drugs


Weight loss drugs are hitting the mainstream, with pilot programmes underway. Liz Terry examines the threats and opportunities this creates for the sector
FEATURE: Policy: Weighing in


A £40m pilot for the delivery of weight loss drugs, such as Wegovy, is creating opportunities for the sector
MORE NEWS
All systems go for GoJoe app with Les Mills partnership, investment and campaigns
Employee wellness app GoJoe has teamed up with Les Mills for a major new content offering, giving access to hundreds of new workouts.
Gymbox partners with Raza Sana to transform lives through fitness
Gymbox has partnered with Haringey Council and not-for-profit organisation, Raza Sana, to give opportunities to those living in disadvantaged communities.
Sport for Confidence gets national recognition for pioneering work breaking down barriers to physical activity
Sport for Confidence CIC has received a national award for its pioneering work hardwiring occupational therapy driven services into community sport and leisure settings.
Mindbody adds bespoke insurance to its list of offerings
Mindbody, has launched a specialist insurance programme for its customers which is being delivered through its platform.
LifeFit Group is rolling out Club Pilates across Germany, ahead of Austria and the Netherlands
After introducing Xponential’s reformer Pilates concept, Club Pilates, to Germany last year, LifeFit Group reports that it's accelerating the rollout of the brand, as master franchisor for Germany, Austria and the Netherlands.
Rugby legend Jonny Wilkinson joins the speaker lineup at the HCM Summit to share insights into his journey to health and wellbeing
Rugby legend, Jonny Wilkinson has been announced as a keynote speaker for the HCM Summit on 24 October in London.
+ More news   
 
FEATURED SUPPLIERS

THFI’s new online coaching course partners with FITR: launch your business confidently post-completion
In today's rapidly evolving fitness industry, where many online courses promise secret formulas for entrepreneurial success, the reality is that few provide the necessary knowledge to thrive in this fast-changing profession. [more...]

Altrafit introduces custom functional fitness equipment at Third Space
Altrafit has taken further steps to cement its reputation as a provider of high-quality, affordable functional fitness equipment that is built to last with the development and introduction of a new functional fitness keg for luxury gym operator, Third Space. [more...]
+ More featured suppliers  
COMPANY PROFILES
Orbit4

Orbit4 is the ultimate software solution for operators to manage their fitness facility. [more...]
+ More profiles  
CATALOGUE GALLERY
+ More catalogues  

DIRECTORY
+ More directory  
DIARY

 

28-29 Jul 2024

Les Nouvelles Esthetiques Spa Conference 2024

Southern Sun Rosebank, Johannesburg, South Africa
03-05 Sep 2024

ASEAN Patio Pool Spa Expo

IMPACT Exhibition Center, Bangkok, Thailand
+ More diary  
 


ADVERTISE . CONTACT US

Leisure Media
Tel: +44 (0)1462 431385

©Cybertrek 2024

ABOUT LEISURE MEDIA
LEISURE MEDIA MAGAZINES
LEISURE MEDIA HANDBOOKS
LEISURE MEDIA WEBSITES
LEISURE MEDIA PRODUCT SEARCH
PRINT SUBSCRIPTIONS
FREE DIGITAL SUBSCRIPTIONS